利用他莫昔芬与恩度昔芬药动学模型识别乳腺癌患者亚治疗浓度因素
本研究采用建模与模拟方法,基于两个已发表的他莫昔芬与恩度昔芬联合药动学模型(CYP2D6和CYP3A4/5活性作为协变量),评估CYP2D6活性等因素对稳态浓度的影响,并以6 ng/mL为阈值识别亚治疗浓度患者。弱代谢者97%、中间代谢者54%未达治疗浓度,提示他莫昔芬80 mg和40 mg调整剂量可使89.7%患者达标(标准剂量为45.2%)。建议CYP2D6基因型/表型指导起始剂量,稳态时进行治疗药物监测。
要点
- 弱代谢者97%、中间代谢者54%未达恩度昔芬治疗浓度(6 ng/mL)。
- 他莫昔芬80 mg和40 mg调整剂量可使89.7%患者达标,标准剂量仅45.2%。
- 建议CYP2D6基因型/表型指导起始剂量,稳态时进行治疗药物监测。
核心结论
- 为早期达到恩度昔芬治疗浓度,建议按CYP2D6基因型/表型指导起始剂量,稳态时进行治疗药物监测。
- 弱代谢者和中间代谢者使用标准剂量他莫昔芬时多数未达治疗浓度,需调整剂量。
研究设计与样本
- 建模与模拟研究,使用两个已发表的他莫昔芬与恩度昔芬联合药动学模型,CYP2D6和CYP3A4/5酶活性作为协变量。
- 比较模型间稳态预测值并与文献值对比,以6 ng/mL为阈值识别亚治疗浓度患者并进行剂量调整模拟。
主要发现
- 两个模型的他莫昔芬和恩度昔芬稳态预测值差异显著,采样时间、依从性和生物利用度差异不能完全解释模型间变异。
- 恩度昔芬稳态波动在给药间期内很小(<6%)。
- 弱代谢者97%、中间代谢者54%未达治疗恩度昔芬浓度。
- 调整剂量他莫昔芬80 mg(弱代谢者)和40 mg(中间代谢者)可使89.7%患者达治疗浓度,标准剂量为45.2%。
- 调整剂量后个体间变异仍存在。
关键数值与推荐
- 恩度昔芬亚治疗浓度阈值定义为6 ng/mL。
- 弱代谢者他莫昔芬调整剂量为80 mg,中间代谢者为40 mg。
临床怎么用
- 临床可依据CYP2D6基因型/表型指导他莫昔芬起始剂量,弱代谢者考虑80 mg、中间代谢者考虑40 mg。
- 起始治疗后应在稳态时进行治疗药物监测,以确认恩度昔芬浓度达标。
局限性
- 模型间稳态预测值差异显著,且采样时间、依从性和生物利用度差异不能完全解释模型间变异。
- 剂量调整后个体间变异仍存在。
- 需在临床试验中充分测量、报告并前瞻性研究依从性、生物利用度、达药动学稳态时间等影响因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: A better understanding of the highly variable pharmacokinetics (PK) of tamoxifen and its active metabolite endoxifen in breast cancer patients is crucial to support individualised treatment. This study used a modelling and simulation approach to quantitatively assess the influence of cytochrome P450 (CYP) 2D6 activity and other relevant factors on tamoxifen and endoxifen PK to identify subgroups at risk for subtherapeutic endoxifen concentrations. METHODS: Simulations were performed using two previously published PK models jointly describing tamoxifen and endoxifen with CYP2D6 and CYP3A4/5 enzyme activities implemented as covariates. Steady-state predictions were compared between models and with the literature values. Factors potentially causing between-model discrepancies were explored. A previously published threshold (6 ng/mL) was used to identify patients with subtherapeutic endoxifen concentrations and to perform a dose adaptation study. RESULTS: Steady-state predictions of tamoxifen and endoxifen were considerably different between the models. The factors, differences in sampling time, adherence and bioavailability, were not able to fully capture between-model variability. Endoxifen steady-state fluctuations within a dosing interval were minimal (<6%). Poor (97%) and intermediate (54%) CYP2D6 metabolisers failed to achieve therapeutic endoxifen concentrations, suggesting adapted doses of tamoxifen 80 and 40 mg, respectively, achieving therapeutic endoxifen concentrations in 89.7% of patients (standard dosing 45.2%). However, interindividual variability remained. CONCLUSIONS: To achieve therapeutic endoxifen concentrations early in treatment, it is advisable to initiate treatment by CYP2D6 genotype/phenotype-guided dosing, followed by therapeutic drug monitoring at steady-state. We strongly advocate to adequately measure, report and prospectively investigate influential factors (i.e. adherence, bioavailability, time to PK steady-state) in clinical trials.
引用
- Klopp-Schulze L, Joerger M, Wicha SG, et al. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clin Pharmacokinet. 2018. PMID: 28540639. doi:10.1007/s40262-017-0555-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。